Genetic markers in breast tumors with hereditary predisposition

Principles of Molecular Oncology: Third Edition

Volumn , Issue , 2008, Pages 85-105

  Grushko, Tatyana A ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054072358     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-470-4_4     Document Type: Chapter

References (159)

1. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25(43):5898-5905.
2. Wooster R, Weber BL. Breast and ovarian cancer. New Engl J Med. 2003; 348(23):2339-2347.
3. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11(2):103-105.
4. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39(3):352-358.
5. Couch FJ, Weber BL. Breast Cancer. In: The genetic basis of human cancer. (Vogelstein B, Kinzler KW, eds.) McGraw Hill, New York, NY, 2002. pp. 549-581.
6. Deng CX. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucl Acids Res. 2006;34(5):1416-1426.
7. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864-5874.
8. Jasin M. Homologous repair of DNA damage and tumorigenesis: The BRCA connection. Oncogene. 2002;21(58):8981-8993.
9. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 2006;25(43):5854-5863.
10. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006;25(43):5912-5919.
11. Rudkin TM, Foulkes WD. BRCA2: Breaks, mistakes and failed separations. Trends Mol Med. 2005;11(4):145-148.
12. Scully R, Puget N. BRCA1 and BRCA2 in hereditary breast cancer. Biochimie 2002;84(1):95-102.
13. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108(2):171-182.
14. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: Approaches for therapeutic interventions. Mol Cancer Ther. 2006;5(6):1396-1404.
15. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: Transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003;15(3):345-350.
16. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379-1388.
17. Carvalho MA, Couch FJ, Monteiro ANA. Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol. 2006;doi:10.1016/ jbiocel.2006.08.002.
18. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349(9064):1505-1510.
19. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18(4):287-295.
20. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90(15):1138-1145.
21. Honrado E, Benâitez J, Palacios J. Histopathology of BRCA1-and BRCA2-associated breast cancer. Crit Rev Oncol Hemat. 2006;59(1):27-39.
22. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 2000;18(21 Suppl):107S-112S.
23. Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003;98(8):1569-1577.
24. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175-5180.
25. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.
26. Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol. 2000;18(21 Suppl):119S-124S.
27. Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 1998;47(2):121-127.
28. Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 1998;58(5):859-862.
29. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33(3):362-371.
30. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77(4):697-709.
31. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997;57(7):1222-1227.
32. Alvarez S, Diaz-Uriarte R, Osorio A, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 2005;11(3):1146-1153.
33. Barlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A. Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chrom Cancer. 1997;20(4):372-376.
34. Jèonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res. 2005;65(17):7612-7621.
35. Johannsdottir HK, Jonsson G, Johannesdottir G, et al. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer. 2006;119(5):1052-1060.
36. Lodewyk FA, Wessels LF, van Welsem T, et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res. 2002;62(23):7110-7117.
37. Nathanson KL, Shugart YY, Omaruddin R, et al. CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Hum Mol Genet. 2002;11(11):1327-1332.
38. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65(7):2554-2559.
39. Tirkkonen M, Kainu T, Loman N, et al. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chrom Cancer. 1999;24(1):56-61.
40. van Beers EH, van Welsem T, Wessels LF, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005;65(3):822-827.
41. Tutt A, Gabriel A, Bertwistle D, et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol. 1999;9(19):1107-1110.
42. Weaver Z, Montagna C, Xu X, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene. 2002;21(33):5097-5107.
43. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999;3(3):389-395.
44. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulinbinding domain in BRCA1. Cancer Res. 2001;61(21):7713-7718.
45. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA. 2002;99(4):1978-1983.
46. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003;63(6):1398-1404.
47. Parvin JD, Sankaran S, Brigham, Women's H. The BRCA1 E3 ubiquitin ligase controls centrosome dynamics. Cell Cycle. 2006;5(17):1946-1950.
48. Starita LM, Machida Y, Sankaran S, et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 2004;24(19):8457- 8466.
49. Wang X, Wang RH, Li W, et al. Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure. J Biol Chem. 2004;279(28):29606-29614.
50. Ouchi M, Fujiuchi N, Sasai K, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem. 2004;279(19):19643-19648.
51. Hut HM, Rembacz KP, van Waarde MA, et al. Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes. Oncogene. 2005;24(51):7619-7623.
52. Wang X, Liu L, Montagna C, Ried T, Deng CX. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality. Cell Death Differ. 2007;14(5):924-931.
53. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386(6627):761-763.
54. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26(4 Suppl 12):51-59.
55. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24(18):2786-2792.
56. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005;353(16):1673-1684.
57. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001;344(11):783-792.
58. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59(8):2011-2017.
59. Robson M, Rajan P, Rosen PP, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res. 1998;58(9):1839-1842.
60. Grushko TA, Blackwood MA, Schumm PL, et al. Molecularcytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002;62(5):1481-1488.
61. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol. 2000;113(5):675-682.
62. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10(7):720-727.
63. Adem C, Soderberg CL, Hafner K, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chrom Cancer. 2004;41(1):1-11.
64. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: Differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003;9(10) Pt 1:3606-3614.
65. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. New Engl J Med. 2001;344(8): 539-548.
66. Isola J, Chu L, DeVries S, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res. 1999;5(12):4140-4145.
67. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004;10(2):499-507.
68. Kauraniemi P, Hedenfalk I, Persson K, et al. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000;60(19):5323-5328.
69. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1-and BRCA2-related breast tumors. Cancer Res. 2002;62(13):3587-3591.
70. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31(1):121-128.
71. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998;29(10):1140-1144.
72. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer. 1999;85(10):2200-2205.
73. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2000;7(3):143-164.
74. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2002;5(1):57-58.
75. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-10874.
76. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 1998;17(15):1939-1948.
77. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem. 2002;277(23):20965-20973.
78. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 2001;61(10):4092-4097.
79. de Cremoux P, Salomon AV, Liva S, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91(7):641-643.
80. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA. 1998;95(23):13869-13874.
81. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA. 1998;95(5):2302-2306.
82. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 1998;16(13):1713- 1721.
83. Offit K. Are BRCA1-and BRCA2-associated breast cancers different? J Clin Oncol. 2000;18(21 Suppl):104S-106S.
84. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene. 2002;21(58):8994-9007.
85. Eerola H, Heikkilèa P, Tamminen A, et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutationnegative breast cancer families. Breast Cancer Res. 2005;7(1): R465-469.
86. Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7(7):1937-1945.
87. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11(11):4003-4011.
88. Salahshor S, Haixin L, Huo H, et al. Low frequency of Ecadherin alterations in familial breast cancer. Breast Cancer Res. 2001;3(3):199-207.
89. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptornegative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18(1):26-35.
90. Rakha EA, Abd El Rehim D, Pinder SE, et al. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46(6):685-693.
91. Kovâacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Mol Pathol. 2003;56(6):318-322.
92. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92(15):1260-1266.
93. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225-3229.
94. Osin PP, Lakhani SR. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Breast Cancer Res. 1999;1(1):36-40.
95. Crook T, Brooks LA, Crossland S, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumours. Oncogene. 1998;17(13):1681-1689.
96. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90(1):5-14.
97. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54(5):1169-1174.
98. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13(1):41-47.
99. Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: Ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002;74(2):155-165.
100. Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene. 2002;21(20):3199-3206.
101. Yang W, Shen J, Wu M, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20(14):1688- 1702.
102. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153-1160.
103. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cellcycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145-1152.
104. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999;17(11):3396-3402.
105. Chappuis PO, Donato E, Goffin JR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol. 2005;16(5): 735-742.
106. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene. 2001;20(51):7514-7523.
107. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 2001;29(4):418-425.
108. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer. 2000;83(10):1318-1322.
109. Rebbeck TR. Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Environ Mol Mutagen. 2002;39(2-3):228- 234.
110. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1-and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001;61(14): 5420-5424.
111. Honrado E, Osorio A, Palacios J, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol. 2005;23(30):7503-7511.
112. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med. 2002;347(25):1999-2009.
113. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433(2):119-129.
114. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
115. Olopade OI, Grushko T. Gene-expression profiles in hereditary breast cancer. New Engl J Med. 2001;344(26):2028-2029.
116. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-8423.
117. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-1485.
118. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18(10):1321-1328.
119. Lacroix M, Leclercq G. The "portrait" of hereditary breast cancer. Breast Cancer Res Treat. 2005;89(3):297-304.
120. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66(9):4636-4644.
121. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
122. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685.
123. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830-835.
124. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116(1):261-270.
125. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209(4):445-453.
126. Rodrâiguez-Pinilla SM, Sarriâo D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12(5):1533-1539.
127. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-5853.
128. van der Groep P, Bouter A, van der Zanden R, et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004;96(9):712-713.
129. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271.
130. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374.
131. Chadwick BP, Lane TF. BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation. Chromosoma. 2005;114(6):432-439.
132. Ganesan S, Silver DP, Greenberg RA, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 2002;111(3):393-405.
133. Pageau GJ, Lawrence JB. BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin. J Cell Biol. 2006;175(5):693-701.
134. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121-132.
135. Smith GH, Chepko G. Mammary epithelial stem cells. Microsc Res Tech. 2001;52(2):190-203.
136. Bèocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: A new cell biological concept. Lab Invest. 2002;82(6):737-746.
137. Sirchia SM, Ramoscelli L, Grati FR, et al. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res. 2005;65(6):2139-2146.
138. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196(1):1-7.
139. Wei M, Grushko TA, Dignam J, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005;65(23):10692-10699.
140. Collins N, Wooster R, Stratton MR. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer. 1997;76(9):1150-1156.
141. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10(7):687-692.
142. Krop I, Maguire P, Lahti-Domenici J, et al. Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. Cancer Res. 2003;63(9):2024-2027.
143. Tesoriero A, Andersen C, Southey M, et al. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet. 1999;65(2):567-569.
144. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001-3007.
145. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25(43):5906-5911.
146. Cipollini G, Tommasi S, Paradiso A, et al. Genetic alterations in hereditary breast cancer. Ann Oncol. 2004;15 Suppl 1: I7-I13.
147. Gâorski B, Debniak T, Masojâc B, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 2003;106(3):379-381.
148. Hall J. The Ataxia-telangiectasia mutated gene and breast cancer: Gene expression profiles and sequence variants. Cancer Lett. 2005;27(2):105-114.
149. Heikkinen K, Rapakko K, Karppinen SM, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006;27(8):1593-1599.
150. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Lowpenetrance susceptibility to breast cancer due to CHEK2 (*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet. 2002;31(1):55-59.
151. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet. 2007;39(2):165-167.
152. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nature Genet. 2007;39(2):162-164.
153. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene. 2002;21(24):3827-3835.
154. Clarke CL, Sandle J, Parry SC, et al. Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype. J Pathol. 2004;204(2):147-152.
155. Funato T, Satou J, Kozawa K, Fujimaki S, Miura T, Kaku M. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep. 2001;8(4):807-810.
156. Gronwald J, Jauch A, Cybulski C, et al. Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer. 2005;114(2):230-236.
157. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2006;99(1):85-90.
158. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006;19(7):999-1009.
159. Savelyeva L, Claas A, Matzner I, et al. Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers. Cancer Res. 2001;61(13):5179-5185.